Cancer related gene alteration analysis study in patients with endometrial cancer
Not Applicable
- Conditions
- endometrial cancer
- Registration Number
- JPRN-UMIN000027294
- Lead Sponsor
- SRL Medisearch Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients judged by their physician to be unfit to participate in this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method [Blood] Gene mutation and chromosome copy number abnormality analysis using the Droplet Digital PCR. PIK3CA gene mutation, AKT1 gene mutation and amplification, AKT2 gene amplification. [FFPE tumor tissue] Analysis using Droplet Digital PCR and PCR. PIK3CA gene mutation, AKT1 gene mutation and amplification, AKT2 gene amplification.
- Secondary Outcome Measures
Name Time Method [FFPE tumor tissue] Gene analysis using NGS Target gene will be updated in the future depending on the contents of the chip.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms are being analyzed in the ECGA study for endometrial cancer patients?
How does the ECGA study compare gene alteration findings with standard-of-care treatment outcomes in endometrial cancer?
What biomarkers are identified for patient selection in the SRL Medisearch endometrial cancer gene analysis trial?
What adverse events are associated with cancer-related gene alterations in endometrial cancer research?
What drug targets are explored in the ECGA study for endometrial cancer molecular subtypes?